在业绩披露窗口期,创新药企的成长韧性正在接受市场检验。率先开始披露上年业绩的港股创新药企体现尤为明显。2月底,在美国和香港两地上市的创新药企再鼎医药(ZLAB/09688.HK)发布了2024年第四季度和全年业绩报告。根据报告显示,2024年第四季度公司总收入为1.091亿美元,同比增长66%。2024年全年公司总收入为3.990亿美元,同比增长50%。此外,公司给出了2025年全年5.60亿美元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.